Some potential genetic markers for prediction of treatment response in HCV affected Egyptian children / Normeen Hany Aly Mohamed Rady ; Supervised Sahar Abdelatty Sharaf , Iman Atef Mandour , Hanaa Mostafa Elkaraksy
Material type: TextLanguage: English Publication details: Cairo : Normeen Hany Aly Mohamed Rady , 2014Description: 172 P. : charts ; 25cmOther title:- بعض الدلالالت الوراثية المحتملة لتوقع الإستجابة للعلاج بالإنترفيرون فى مرضى الإلتهاب الكبدى الفيروسى سى فى الأطفال المصريين [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.07.Ph.D.2014.No.S (Browse shelf(Opens below)) | Not for loan | 01010110065160000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.07.Ph.D.2014.No.S (Browse shelf(Opens below)) | 65160.CD | Not for loan | 01020110065160000 |
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Egypt has a high prevalence of hepatitis C virus (HCV) infection in children. Limitations of the current HCV treatment are low rate of sustained virological response (SVR) approximately 50%, significant side effects and high expenses, making prediction of treatment response crucial. This study aimed to investigate association of single nucleotide polymorphisms (SNPs) in IL10, IL28B and IL29 genes in predicting treatment response in HCV infected children. Seventy three Egyptian pediatric patients, receiving pegylated interferon Ü 2b (PEG-IFN Ü 2b) and ribavirin were included, for whom liver biopsy was performed for evaluation of fibrosis score. Genotyping of SNPs in IL10 gene (rs1800896, rs302109, and rs1800872), IL28B gene (rs12979860, rs8099917) and IL29 gene (rs30461) as well as HCV genotype were analyzed by Real - time PCR. The CC genotype (IL28B; rs12979860) had 6.62 folds higher chance to develop SVR than CT and TT genotypes (p = 0.004). The G allele (SNP rs8099917; IL28B), was 2.257 times more likely to be resistant to HCV therapy than the protective T allele (P = 0.04). The CC/TT IL28B haplotype had 6.632 times more chance to respond to HCV therapy compared to other haplotypes P = 0.008
Issued also as CD
There are no comments on this title.